Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | HRAS A59T RET A883F RET A883T |
Therapy | Pralsetinib |
Indication/Tumor Type | medullary thyroid carcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS A59T RET A883F RET A883T | medullary thyroid carcinoma | predicted - resistant | Pralsetinib | Case Reports/Case Series | Actionable | In a retrospective analysis, a medullary thyroid carcinoma patient harboring RET A883T progressed on treatment with Gavreto (pralsetinib) and was found to have acquired RET A883F and HRAS A59T (PMID: 38127829; NCT03157128, NCT03037385, NCT03780517). | 38127829 |
PubMed Id | Reference Title | Details |
---|---|---|
(38127829) | Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma. | Full reference... |